0001415889-24-016259.txt : 20240610 0001415889-24-016259.hdr.sgml : 20240610 20240610175554 ACCESSION NUMBER: 0001415889-24-016259 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240607 FILED AS OF DATE: 20240610 DATE AS OF CHANGE: 20240610 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Masoud Maher CENTRAL INDEX KEY: 0001874571 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40674 FILM NUMBER: 241033980 MAIL ADDRESS: STREET 1: C/O MAXCYTE, INC. STREET 2: 22 FIRSTFIELD ROAD, SUITE 110 CITY: GAITHERSBURG STATE: MD ZIP: 20878 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MAXCYTE, INC. CENTRAL INDEX KEY: 0001287098 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 522210438 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9713 KEY WEST AVENUE, STREET 2: SUITE 400 CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 301-517-5556 MAIL ADDRESS: STREET 1: 9713 KEY WEST AVENUE, STREET 2: SUITE 400 CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: MAXCYTE INC DATE OF NAME CHANGE: 20040415 4 1 form4-06102024_090649.xml X0508 4 2024-06-07 0001287098 MAXCYTE, INC. MXCT 0001874571 Masoud Maher C/O MAXCYTE, INC. 9713 KEY WEST AVENUE, SUITE 400 ROCKVILLE MD 20850 true true false false President and CEO 0 Common Stock 2024-06-07 4 P 0 29557 4.866 A 29557 D Common Stock 2024-06-10 4 P 0 70443 4.901 A 100000 D The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.84 to $4.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.77 to $5.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. /s/ Brian Leaf, Attorney-in-Fact 2024-06-10